Absci (ABSI) Stock: Buy, Sell, or Hold?
ABSI - Absci Corporation Common Stock
$11.07
0.32 (2.98%)
▲
5d:
+13.66%
30d:
+25.8%
90d:
-4.07%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Oct 1, 2026 at $10.75 · last confirmed Oct 1, 2026
Strength: 6.5/10
Get Alerted When ABSI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ABSI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ABSI shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABSI is currently trading at $11.07, which is considered extended relative to its 30-day fair value range of $8.44 to $10.16.
Technical Outlook: Technically, ABSI is in a uptrend. The price is approaching resistance at $11.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ABSI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.40 (+30.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABSI is in a uptrend. The price is approaching resistance at $11.35. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ABSI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $14.40 (+30.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.44 -
$10.16
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range (+9.0% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.1% below Wall St target ($14.40)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.44 -
$10.16
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.25
Resistance Level
$11.35
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.40
Wall Street Target
$14.40
(+30.1%)
Revenue Growth (YoY)
-46.4%
Share & Embed Analysis
Last updated: October 03, 2026 1:11 PM ET
Data refreshes hourly during market hours. Next update: 2:11 PM
Data refreshes hourly during market hours. Next update: 2:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABSI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
